This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 24, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development services company with operations in
the United States, today announced the acquisition of MedKey Med-Tech Development Co. Ltd. and Jiecheng Med-Tech Development Co. Ltd., two related contract clinical research services companies based in
Shanghai, China. The financial terms of the transaction were not disclosed.
Founded in 2006, MedKey/Jiecheng have about 80 employees and operate in 15 cities in
China, with offices in
Guangzhou. The companies provide services in regulatory affairs, Phase I-IV clinical trial management, and clinical trial site management throughout most of the regions in
China. Their customer base includes both multinational pharmaceutical companies and domestic Chinese pharmaceutical companies. David Xi, founder, owner, and CEO of the companies, will continue to manage MedKey/Jiecheng as WuXi's Executive Director of Clinical Operations. As part of WuXi, MedKey/Jiecheng will leverage WuXi's broad customer base and will focus on clinical services needed by customers for Chinese regulatory filings and market access.
"WuXi's acquisition of Medkey/Jiecheng continues our strategy to build an integrated platform of R&D services that will allow anyone and any company to discover and develop drugs more efficiently and cost effectively for patients," said Dr.
Ge Li, Chairman and CEO of WuXi. "This acquisition provides WuXi an existing clinical development service capability and infrastructure that WuXi will expand and strengthen to serve our customers' growing clinical development needs in the fast-growing Chinese healthcare market."
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in
the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
Cautionary Note Regarding Forward-Looking Statements
Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including the strategic rationale for, and anticipated benefits of, the MedKey/Jiecheng acquisition and the expected growth in MedKey/Jiecheng's target market.